Brought to you by 
Opko takes 33% stake in antibody developer Sorrento; later divests stake
11 Mar 2014
Executive Summary
Opko Health (drug candidates and diagnostics for eye disorders) has received exclusive rights to start-up Sorrento's fully human monoclonal antibody library, which the former will use to discover and develop ophthalmic treatments.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Opko takes 33% stake in antibody developer Sorrento; later divests stake
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice